Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease
The aim of this study was to investigate the clinical and biochemical efficiency of citicoline in cognitive improvement and changes of glutathione peroxidase (GPx) blood plasma levels in patients at early stages of Parkinson’s disease (PD). Materials and methods. We recruited 42 patients at I–II...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2021-12-01
|
| Series: | Patologìâ |
| Subjects: | |
| Online Access: | http://pat.zsmu.edu.ua/article/view/247142/246806 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471314745622528 |
|---|---|
| author | A. V. Demchenko V. V. Biriuk |
| author_facet | A. V. Demchenko V. V. Biriuk |
| author_sort | A. V. Demchenko |
| collection | DOAJ |
| description | The aim of this study was to investigate the clinical and biochemical efficiency of citicoline in cognitive improvement and changes of glutathione peroxidase (GPx) blood plasma levels in patients at early stages of Parkinson’s disease (PD).
Materials and methods. We recruited 42 patients at I–II Hoehn and Yahr PD stages and 20 controls. The Montreal Cognitive Assessment test (MoCA) was used to assess several cognitive domains in PD patients (before citicoline treatment, after intravenous therapy and after pills therapy) and controls (once). Plasma was collected once in controls and twice in PD patients (on the first and the last days of observation). Citicoline was administrated to 23 of 42 PD patients in addition to basic antiparkinsonian therapy intravenously during 10 days and with pills during next 30 days. The rest 19 of 42 PD patients had been taking basic antiparkinsonian treatment only (comparison group).
Results. We observed significant improvement of MoCA scores in PD patients with citicoline course (PD-Cs) in each check day. But in spite of such an improvement in PD patients, who were left on the basic antiparkinsonian treatment (PD-Bs), on the 10th day of observation, patients of this group did not keep it to the last day of the research (P < 0.001). After the treatment the GPx level in plasma of PD-Cs was significantly higher than in PD-Bs (P < 0.001). Furthermore, the activity of GPx plasma level after citicoline course was significantly higher than before additional neuroprotective therapy, which wasn’t observed in PD patients on basic treatment only.
Conclusion. The cognition of PD patients (according to MoCA scores) at the early stages of the disease was significantly improved after citicoline treatment. Citicoline treatment had significant positive influence on the increasing antioxidant GPx plasma activity in PD patients at the early stages of the disease. |
| format | Article |
| id | doaj-art-e229774458ad4538abae246725cbef6d |
| institution | Kabale University |
| issn | 2306-8027 2310-1237 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Patologìâ |
| spelling | doaj-art-e229774458ad4538abae246725cbef6d2025-08-20T03:24:52ZengZaporizhzhia State Medical and Pharmaceutical UniversityPatologìâ2306-80272310-12372021-12-0118335235510.14739/2310-1237.2021.3.247142Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s diseaseA. V. Demchenko0https://orcid.org/0000-0002-4296-0902V. V. Biriuk1https://orcid.org/0000-0001-8826-1536Zaporizhzhia State Medical University, Ukraine, UkraineZaporizhzhia State Medical University, Ukraine, UkraineThe aim of this study was to investigate the clinical and biochemical efficiency of citicoline in cognitive improvement and changes of glutathione peroxidase (GPx) blood plasma levels in patients at early stages of Parkinson’s disease (PD). Materials and methods. We recruited 42 patients at I–II Hoehn and Yahr PD stages and 20 controls. The Montreal Cognitive Assessment test (MoCA) was used to assess several cognitive domains in PD patients (before citicoline treatment, after intravenous therapy and after pills therapy) and controls (once). Plasma was collected once in controls and twice in PD patients (on the first and the last days of observation). Citicoline was administrated to 23 of 42 PD patients in addition to basic antiparkinsonian therapy intravenously during 10 days and with pills during next 30 days. The rest 19 of 42 PD patients had been taking basic antiparkinsonian treatment only (comparison group). Results. We observed significant improvement of MoCA scores in PD patients with citicoline course (PD-Cs) in each check day. But in spite of such an improvement in PD patients, who were left on the basic antiparkinsonian treatment (PD-Bs), on the 10th day of observation, patients of this group did not keep it to the last day of the research (P < 0.001). After the treatment the GPx level in plasma of PD-Cs was significantly higher than in PD-Bs (P < 0.001). Furthermore, the activity of GPx plasma level after citicoline course was significantly higher than before additional neuroprotective therapy, which wasn’t observed in PD patients on basic treatment only. Conclusion. The cognition of PD patients (according to MoCA scores) at the early stages of the disease was significantly improved after citicoline treatment. Citicoline treatment had significant positive influence on the increasing antioxidant GPx plasma activity in PD patients at the early stages of the disease.http://pat.zsmu.edu.ua/article/view/247142/246806parkinson’s diseaseearly stagesneuroprotectorcognitive impairmentglutathione peroxidase |
| spellingShingle | A. V. Demchenko V. V. Biriuk Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease Patologìâ parkinson’s disease early stages neuroprotector cognitive impairment glutathione peroxidase |
| title | Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease |
| title_full | Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease |
| title_fullStr | Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease |
| title_full_unstemmed | Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease |
| title_short | Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease |
| title_sort | impact of neuroprotective therapy on cognition and oxidative stress in the early stages of parkinson s disease |
| topic | parkinson’s disease early stages neuroprotector cognitive impairment glutathione peroxidase |
| url | http://pat.zsmu.edu.ua/article/view/247142/246806 |
| work_keys_str_mv | AT avdemchenko impactofneuroprotectivetherapyoncognitionandoxidativestressintheearlystagesofparkinsonsdisease AT vvbiriuk impactofneuroprotectivetherapyoncognitionandoxidativestressintheearlystagesofparkinsonsdisease |